Orbital involvement by NUT midline carcinoma: new presentation and encouraging outcome managed by radiotherapy combined with tyrosine kinase inhibitor: a case report

BACKGROUND: NUT midline carcinoma (NMC) is a poorly differentiated squamous cancer with a median survival at less than 7 months. NMC is resistant to conventional chemotherapies and characterized by rearrangement of the NUT gene. CASE PRESENTATION: Here, we described a patient who initially presented...

Descripción completa

Detalles Bibliográficos
Autores principales: Chai, Peiwei, Zhou, Chuandi, Jia, Renbing, Wang, Yefei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942267/
https://www.ncbi.nlm.nih.gov/pubmed/31900183
http://dx.doi.org/10.1186/s13000-019-0922-1
_version_ 1783484667644608512
author Chai, Peiwei
Zhou, Chuandi
Jia, Renbing
Wang, Yefei
author_facet Chai, Peiwei
Zhou, Chuandi
Jia, Renbing
Wang, Yefei
author_sort Chai, Peiwei
collection PubMed
description BACKGROUND: NUT midline carcinoma (NMC) is a poorly differentiated squamous cancer with a median survival at less than 7 months. NMC is resistant to conventional chemotherapies and characterized by rearrangement of the NUT gene. CASE PRESENTATION: Here, we described a patient who initially presented with epiphora, and an orbit involved NMC. In addition, we for the first time demonstrated that local radiotherapy combined with tyrosine kinase inhibitor (TKI) could significantly inhibit tumor progression in orbital involvement by NMC. CONCLUSIONS: Our study for the first time described an orbit involved NMC patient initially presented with epiphora. In addition, we provided an alternative to the management of orbit involved NMC.
format Online
Article
Text
id pubmed-6942267
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-69422672020-01-07 Orbital involvement by NUT midline carcinoma: new presentation and encouraging outcome managed by radiotherapy combined with tyrosine kinase inhibitor: a case report Chai, Peiwei Zhou, Chuandi Jia, Renbing Wang, Yefei Diagn Pathol Case Report BACKGROUND: NUT midline carcinoma (NMC) is a poorly differentiated squamous cancer with a median survival at less than 7 months. NMC is resistant to conventional chemotherapies and characterized by rearrangement of the NUT gene. CASE PRESENTATION: Here, we described a patient who initially presented with epiphora, and an orbit involved NMC. In addition, we for the first time demonstrated that local radiotherapy combined with tyrosine kinase inhibitor (TKI) could significantly inhibit tumor progression in orbital involvement by NMC. CONCLUSIONS: Our study for the first time described an orbit involved NMC patient initially presented with epiphora. In addition, we provided an alternative to the management of orbit involved NMC. BioMed Central 2020-01-04 /pmc/articles/PMC6942267/ /pubmed/31900183 http://dx.doi.org/10.1186/s13000-019-0922-1 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Chai, Peiwei
Zhou, Chuandi
Jia, Renbing
Wang, Yefei
Orbital involvement by NUT midline carcinoma: new presentation and encouraging outcome managed by radiotherapy combined with tyrosine kinase inhibitor: a case report
title Orbital involvement by NUT midline carcinoma: new presentation and encouraging outcome managed by radiotherapy combined with tyrosine kinase inhibitor: a case report
title_full Orbital involvement by NUT midline carcinoma: new presentation and encouraging outcome managed by radiotherapy combined with tyrosine kinase inhibitor: a case report
title_fullStr Orbital involvement by NUT midline carcinoma: new presentation and encouraging outcome managed by radiotherapy combined with tyrosine kinase inhibitor: a case report
title_full_unstemmed Orbital involvement by NUT midline carcinoma: new presentation and encouraging outcome managed by radiotherapy combined with tyrosine kinase inhibitor: a case report
title_short Orbital involvement by NUT midline carcinoma: new presentation and encouraging outcome managed by radiotherapy combined with tyrosine kinase inhibitor: a case report
title_sort orbital involvement by nut midline carcinoma: new presentation and encouraging outcome managed by radiotherapy combined with tyrosine kinase inhibitor: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6942267/
https://www.ncbi.nlm.nih.gov/pubmed/31900183
http://dx.doi.org/10.1186/s13000-019-0922-1
work_keys_str_mv AT chaipeiwei orbitalinvolvementbynutmidlinecarcinomanewpresentationandencouragingoutcomemanagedbyradiotherapycombinedwithtyrosinekinaseinhibitoracasereport
AT zhouchuandi orbitalinvolvementbynutmidlinecarcinomanewpresentationandencouragingoutcomemanagedbyradiotherapycombinedwithtyrosinekinaseinhibitoracasereport
AT jiarenbing orbitalinvolvementbynutmidlinecarcinomanewpresentationandencouragingoutcomemanagedbyradiotherapycombinedwithtyrosinekinaseinhibitoracasereport
AT wangyefei orbitalinvolvementbynutmidlinecarcinomanewpresentationandencouragingoutcomemanagedbyradiotherapycombinedwithtyrosinekinaseinhibitoracasereport

Ejemplares similares